5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Buy
78
HALO Quote, Financials, Valuation and Earnings
Last price:
$67.66
Seasonality move
:
7.09%
Day range:
$67.13 - $69.85
52-week range:
$41.28 - $70.51
Dividend yield:
0%
P/E ratio:
18.65x
P/S ratio:
8.33x
P/B ratio:
17.92x
Volume:
9.7M
Avg. volume:
1.8M
1-year change:
70.2%
Market cap:
$8.6B
Revenue:
$1B
EPS (TTM):
$3.76
Analysts' Opinion
-
Consensus RatingHalozyme Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $68.88, Halozyme Therapeutics has an estimated downside of -1.8% from its current price of $70.14.
-
Price Target UpsideAccording to analysts, the highest upside price target is $78.00 representing 11.21% upside increase from its current price of $70.14.
Fair Value
-
According to the consensus of 6 analysts, Halozyme Therapeutics has -1.8% downside to fair value with a price target of $68.88 per share.
HALO vs. S&P 500
-
Over the past 5 trading days, Halozyme Therapeutics has overperformed the S&P 500 by 15.32% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Halozyme Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Halozyme Therapeutics has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Halozyme Therapeutics reported revenues of $264.9M.
Earnings Growth
-
Halozyme Therapeutics has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Halozyme Therapeutics reported earnings per share of $0.93.
Enterprise value:
9.4B
EV / Invested capital:
4.73x
Price / LTM sales:
8.33x
EV / EBIT:
15.09x
EV / Revenue:
8.67x
PEG ratio (5yr expected):
0.34x
EV / Free cash flow:
18.97x
Price / Operating cash flow:
18.22x
Enterprise value / EBITDA:
13.34x
Gross Profit (TTM):
$904.8M
Return On Assets:
23.82%
Net Income Margin (TTM):
44.76%
Return On Equity:
137.42%
Return On Invested Capital:
26.13%
Operating Margin:
53.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $705M | $863M | $1.1B | $195.9M | $264.9M | |
| Gross Profit | $546.4M | $677.5M | $904.8M | $167.6M | $216.5M | |
| Operating Income | $245.7M | $379.3M | $597.5M | $95.5M | $141.5M | |
| EBITDA | $315.8M | $495.5M | $704.6M | $120.7M | $168.8M | |
| Diluted EPS | $1.31 | $2.42 | $3.76 | $0.60 | $0.93 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $941.7M | $988.7M | $615M | $873.6M | $1.3B | |
| Total Assets | $966.6M | $1.2B | $1.7B | $1.8B | $2.2B | |
| Current Liabilities | $107.4M | $111.7M | $91.9M | $131.6M | $150.4M | |
| Total Liabilities | $899M | $902M | $1.6B | $1.7B | $1.7B | |
| Total Equity | $67.6M | $260.3M | $65.9M | $177.8M | $482.3M | |
| Total Debt | $873.8M | $877.6M | $1.5B | $1.5B | $1.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $279.3M | $431M | $503.9M | $129.4M | $154.2M | |
| Cash From Investing | -$497.9M | -$119.4M | -$270.5M | -$82.7M | -$90.4M | |
| Cash From Financing | $197.1M | -$243.9M | -$221.7M | -$489K | -$3.3M | |
| Free Cash Flow | $263.6M | $423.6M | $495.8M | $125.9M | $153.3M | |
HALO
Sector
Market Cap
$8.6B
$34.5M
Price % of 52-Week High
99.48%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
4.22%
-0.79%
1-Year Price Total Return
70.2%
-42.08%
Beta (5-Year)
1.256
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$61.77
200-day SMA
Buy
Level
$56.28
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$60.33
Relative Strength Index (RSI14)
Buy
Level
63.83
ADX Line
Neutral
Level
0
Williams %R
Sell
Level
-2.6006
50-day SMA
Buy
Level
$60.99
MACD (12, 26)
Buy
Level
0.72
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.2847)
Sell
CA Score
(Annual)
Level (-0.6438)
Buy
Beneish M-Score
(Annual)
Level (-2.3886)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (0.2417)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Stock Forecast FAQ
In the current month, HALO has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The HALO average analyst price target in the past 3 months is $68.88.
-
Where Will Halozyme Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Halozyme Therapeutics share price will drop to $68.88 per share over the next 12 months.
-
What Do Analysts Say About Halozyme Therapeutics?
Analysts are divided on their view about Halozyme Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Halozyme Therapeutics is a Sell and believe this share price will rise from its current level to $58.00.
-
What Is Halozyme Therapeutics's Price Target?
The price target for Halozyme Therapeutics over the next 1-year time period is forecast to be $68.88 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is HALO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Halozyme Therapeutics is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of HALO?
You can purchase shares of Halozyme Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Halozyme Therapeutics shares.
-
What Is The Halozyme Therapeutics Share Price Today?
Halozyme Therapeutics was last trading at $67.66 per share. This represents the most recent stock quote for Halozyme Therapeutics. Yesterday, Halozyme Therapeutics closed at $70.14 per share.
-
How To Buy Halozyme Therapeutics Stock Online?
In order to purchase Halozyme Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
